MarketPulse

IgA nephropathy

4 articles
The Motley FoolThe Motley Fool··Adria Cimino

Vertex Pharma's $600 Target Hinges on Diversification Beyond Cystic Fibrosis

Vertex Pharmaceuticals eyes 25% stock upside to $600 as it expands beyond cystic fibrosis with new drug approvals and kidney disease candidate povetacicept.
VRTXbiotechrevenue growth
GlobeNewswire Inc.GlobeNewswire Inc.··Jade Biosciences, Inc.

Jade Biosciences Posts $127.4M Loss, Eyes 2028 Cash Runway With Pipeline Catalysts

Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.
JBIOmonoclonal antibodyclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Vera Therapeutics Bolsters Board with Royalty Pharma Executive Ahead of Key Drug Launch

Vera Therapeutics appoints Christopher Hite, Royalty Pharma EVP, to board as the biotech prepares for atacicept launch in IgA nephropathy treatment.
RPRXVERAbiopharmaceuticalIgA nephropathy
BenzingaBenzinga··Vandana Singh

Novartis Kidney Drug Demonstrates Sustained Efficacy in Long-Term Study Data

Novartis's kidney drug Vanrafia shows sustained efficacy in slowing kidney function decline, supporting its path to full regulatory approval in 2026 for IgA nephropathy treatment.
NVSkidney diseaseEGFR